SG11201605784YA - Cell surface prostate cancer antigen for diagnosis - Google Patents
Cell surface prostate cancer antigen for diagnosisInfo
- Publication number
- SG11201605784YA SG11201605784YA SG11201605784YA SG11201605784YA SG11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA
- Authority
- SG
- Singapore
- Prior art keywords
- diagnosis
- cell surface
- prostate cancer
- cancer antigen
- surface prostate
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928776P | 2014-01-17 | 2014-01-17 | |
| PCT/AU2015/000018 WO2015106311A1 (en) | 2014-01-17 | 2015-01-16 | Cell surface prostate cancer antigen for diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605784YA true SG11201605784YA (en) | 2016-08-30 |
Family
ID=53542211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605784YA SG11201605784YA (en) | 2014-01-17 | 2015-01-16 | Cell surface prostate cancer antigen for diagnosis |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10151754B2 (en) |
| EP (1) | EP3094976B1 (en) |
| JP (2) | JP6691060B2 (en) |
| KR (1) | KR102366820B1 (en) |
| CN (1) | CN106164672B (en) |
| AU (1) | AU2015207665B2 (en) |
| CA (1) | CA2936805C (en) |
| DK (1) | DK3094976T3 (en) |
| ES (1) | ES2803217T3 (en) |
| HK (1) | HK1225791A1 (en) |
| SG (1) | SG11201605784YA (en) |
| WO (1) | WO2015106311A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3209686T3 (en) * | 2014-10-23 | 2020-03-16 | Glyp Holdings Pty Ltd | MONOCLONAL ANTI-GPC-1 ANTIBODIES AND APPLICATIONS THEREOF |
| EP3285805B1 (en) | 2015-04-20 | 2021-05-26 | GlyTherix Ltd | Therapeutic antibodies and uses thereof |
| CN106053815B (en) * | 2016-07-01 | 2018-03-27 | 复旦大学附属中山医院 | Purposes of the GPC1 as diagnosing tumor mark |
| JPWO2018199318A1 (en) * | 2017-04-28 | 2020-03-12 | 国立大学法人高知大学 | Anti-GPC-1 antibody |
| CN107907684A (en) * | 2017-09-29 | 2018-04-13 | 何皓 | A kind of prostatic cancer early diagnosis system based on multi-fluorescence service life resolved detection technology |
| CN111187350A (en) * | 2019-12-30 | 2020-05-22 | 西安英创生物技术有限公司 | Antigen binding protein combined with glypican-1 |
| JP7053058B2 (en) * | 2020-05-28 | 2022-04-12 | グリピー ホールディングス ピーティーワイ リミテッド | Glypican epitopes and their use |
| WO2024075067A1 (en) * | 2022-10-06 | 2024-04-11 | Centro Di Riferimento Oncologico | Cancer vaccine composition that comprises a host cell expressing glypican-1 (gpc-1) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE337223B (en) | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5622836A (en) | 1989-05-24 | 1997-04-22 | The University Of Sydney | Monoclonal antibodies which recognize malignant cells from bladder carcinomas |
| US6116013A (en) | 1998-01-02 | 2000-09-12 | Siemens Westinghouse Power Corporation | Bolted gas turbine combustor transition coupling |
| US7108986B2 (en) * | 1998-10-16 | 2006-09-19 | The Regents Of The University Of California | Glypican-1 in human breast cancer |
| EP1439857B1 (en) | 2001-10-12 | 2009-02-25 | Schering Corporation | USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
| AU2002330482A1 (en) * | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
| AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
| CN102698267B (en) * | 2004-08-24 | 2017-07-21 | 中外制药株式会社 | Use the complementary therapy of anti-Anti-glypican-3 antibody |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US7723043B2 (en) * | 2006-01-04 | 2010-05-25 | Picobella, Lp | Methods for screening for prostate cancer |
| WO2008060607A2 (en) | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
| WO2008092894A1 (en) * | 2007-02-02 | 2008-08-07 | Novartis Ag | Modulators of sclerostin binding partners for treating bone-related disorders |
| WO2008140774A2 (en) * | 2007-05-08 | 2008-11-20 | Picobella Llc | Methods for diagnosing and treating prostate and lung cancer |
| KR101105428B1 (en) * | 2009-02-12 | 2012-01-17 | 경북대학교 산학협력단 | A specific peptide targeting glypican-3 |
| WO2013119964A2 (en) * | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2012151609A1 (en) * | 2011-05-06 | 2012-11-15 | Women's And Children's Health Research Institute Inc | Method of treatment and prophylaxis of pathologies of the bone |
-
2015
- 2015-01-16 DK DK15737205.3T patent/DK3094976T3/en active
- 2015-01-16 EP EP15737205.3A patent/EP3094976B1/en active Active
- 2015-01-16 ES ES15737205T patent/ES2803217T3/en active Active
- 2015-01-16 AU AU2015207665A patent/AU2015207665B2/en active Active
- 2015-01-16 CA CA2936805A patent/CA2936805C/en active Active
- 2015-01-16 CN CN201580010766.0A patent/CN106164672B/en active Active
- 2015-01-16 SG SG11201605784YA patent/SG11201605784YA/en unknown
- 2015-01-16 JP JP2016564354A patent/JP6691060B2/en active Active
- 2015-01-16 KR KR1020167022084A patent/KR102366820B1/en active IP Right Grant
- 2015-01-16 US US15/111,973 patent/US10151754B2/en active Active
- 2015-01-16 WO PCT/AU2015/000018 patent/WO2015106311A1/en active Application Filing
-
2016
- 2016-12-06 HK HK16113890A patent/HK1225791A1/en unknown
-
2018
- 2018-10-30 US US16/175,433 patent/US20190120846A1/en not_active Abandoned
-
2019
- 2019-12-20 JP JP2019230614A patent/JP2020060585A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2936805A1 (en) | 2015-07-23 |
| EP3094976A4 (en) | 2017-07-05 |
| WO2015106311A1 (en) | 2015-07-23 |
| AU2015207665B2 (en) | 2021-04-15 |
| KR102366820B1 (en) | 2022-02-22 |
| HK1225791A1 (en) | 2017-09-15 |
| US20160349263A1 (en) | 2016-12-01 |
| JP2017504812A (en) | 2017-02-09 |
| ES2803217T3 (en) | 2021-01-25 |
| CA2936805C (en) | 2024-02-20 |
| US20190120846A1 (en) | 2019-04-25 |
| CN106164672A (en) | 2016-11-23 |
| EP3094976A1 (en) | 2016-11-23 |
| AU2015207665A1 (en) | 2016-08-04 |
| KR20160114088A (en) | 2016-10-04 |
| JP6691060B2 (en) | 2020-04-28 |
| DK3094976T3 (en) | 2020-06-22 |
| US10151754B2 (en) | 2018-12-11 |
| JP2020060585A (en) | 2020-04-16 |
| EP3094976B1 (en) | 2020-03-25 |
| CN106164672B (en) | 2018-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290459A (en) | Cs1 targeted chimeric antigen receptor-modified t cells | |
| ZA201702382B (en) | Combination therapy for cancer | |
| SG11201605585SA (en) | Targeted therapy for small cell lung cancer | |
| EP3189082A4 (en) | Anti-pd-l1 conjugates for treating tumors | |
| ZA201701753B (en) | Biomarkers for assessing breast cancer | |
| HUE046505T2 (en) | Antibody compositions for tumor treatment | |
| HK1225791A1 (en) | Cell surface prostate cancer antigen for diagnosis | |
| IL273265A (en) | Novel combinations for antigen based therapy | |
| GB201420859D0 (en) | Tumour analysis | |
| HK1231381A1 (en) | Combination therapy for cancer | |
| IL246761A0 (en) | Combination therapy for cancer | |
| HUE057708T2 (en) | Cells for producing human antibody | |
| SG11201702077RA (en) | Kit for cancer detection | |
| GB201508480D0 (en) | Cancer | |
| GB2528304B (en) | Perineal prostate biopsy apparatus | |
| IL247723A0 (en) | Cancer stem cell targeting compounds | |
| GB201407003D0 (en) | Biomarkers for prostate cancer | |
| GB201402559D0 (en) | Biomarkers for prostate cancer | |
| GB201506666D0 (en) | Biomarkers for prostate cancer | |
| GB201400373D0 (en) | Biomarker panel for prostate cancer | |
| GB201405286D0 (en) | Cancer diagnostic | |
| GB201417819D0 (en) | Agents for cancer therapy | |
| GB201400387D0 (en) | Diagnostic for gastric cancer | |
| GB201411884D0 (en) | Cancer therapy |